[
  {
    "uuid": "b7c297c4c2d3876b11a07dcbebbb6d9ea32bbaa9",
    "url": "https://www.independentmail.com/story/news/world/israel-hamas/2023/12/28/israel-hamas-gaza-war-live-updates/72046568007/",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "John Bacon",
    "published": "2023-12-28T19:11:00Z",
    "title": "Israel Hamas war updates: Family, Biden mourn US hostage Hamas killed",
    "text": "Israeli troops who accidentally shot three militant-held hostages should not have opened fire because the shooting “did not match the risk” they faced as a firefight unfolded, according to a conclusion issued Thursday by the Israeli military. The shooting took place in Gaza less than two weeks ago, shocking Israel and fueling protests aimed at pressuring the government to make a deal with Hamas for the release of the remaining hostages. “The shooting of the hostages should not have been carried out, this shooting did not match the risk and the situation,” Chief of Staff, Lt. Col. Herzi Halevi wrote. “However, it was carried out under complex circumstances, and under intense combat conditions under prolonged threat.” The three men were shirtless and had emerged from a building with a white flag when Israeli troops encountered them in Shejaiya, an area of north Gaza where clashes between the military and militants had taken place for several days. Two of the hostages were shot and killed immediately, and the third ran back into the building screaming for help in Hebrew. A commander ordered troops to cease fire, but two soldiers who did not hear the order because of noise from a nearby tank shot the third person, Halevi wrote. Only later were the bodies confirmed to be those of three Israelis, Yotam Haim, Samer Talalka and Alon Shamriz. Halevi said commanders must make sure operational instructions are clear “so that we don’t kill ourselves.” “The (military) failed in the mission of rescuing the abductees in this incident,” Halevi concluded. “The entire chain of command feels responsible for the difficult event, grieves over this outcome and shares in the grief of the three families of the abductees.”",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "War, Conflict and Unrest",
      "Human Interest"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "biden",
          "sentiment": "negative"
        },
        {
          "name": "herzi halevi",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "hamas",
          "sentiment": "negative"
        }
      ],
      "locations": [
        {
          "name": "us",
          "sentiment": "none"
        },
        {
          "name": "gaza",
          "sentiment": "none"
        },
        {
          "name": "israel",
          "sentiment": "none"
        },
        {
          "name": "shejaiya",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2023-12-29T00:23:20.681+02:00",
    "updated": "2023-12-29T00:23:20.681+02:00"
  },
  {
    "uuid": "433737f4d961ccfae9b7f7fe64b88017fde74eb6",
    "url": "https://time.news/talentlytica-shows-off-at-ical-2024-indonesian-psychometric-technology-goes-global",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "times news cr",
    "published": "2024-10-17T20:24:00Z",
    "title": "Talentlytica Shows Off at ICAL 2024, Indonesian Psychometric Technology Goes Global",
    "text": "Talentlytica participates in ICAL 2024 , Indonesia’s psychometric technology becomes global. Photo: source for jpnn\njpnn.com BALI – Talentlytica, a company in the field of data-based online assessment solutions, participated in the International Conference on Assessment and Learning (ICAL) 2024, in Bali, on 10-12 October.\nThis event is an opportunity for education experts and practitioners from 18 countries to share the latest knowledge and innovations in the field of assessment.\nICAL 2024, organized by the Australian Council for Educational Research (ACER), has been around for more than 90 years as an independent research team, the Australian Council for Educational Research (ACER), and has grown to become one of the world’s leading educational research organizations.\nNovita Sari, Talent Scientist at Talentlytica who is a Masters graduate in Applied Psychometry from Padjadjaran University, had the opportunity to present the results of her innovative research on the Pauline Test.\nNovita Sari’s presentation entitled, “Psychometric Properties of the Pauline Test: A Next Generation Work Aptitude Test on the Talentlytica Platform,” highlighted the rigorous development and validation process behind Pauline.\n“The development of Pauline is proof of Talentlytica’s commitment to utilizing data and technology to create innovative assessment solutions that can help organizations identify and develop the best potential of their human resources,” said Novita Sari, in her statement, Friday (11/10).\nThis research shows that Pauline is an innovation from the conventional Pauli Test: it is not only reliable and valid, but also offers significant practical advantages compared to conventional paper-based measuring tools, such as a faster, more accurate assessment process, and provides an interesting experience for participants.\nThe presence of Novita, as an experienced psychometric expert, at this international conference shows the quality and dedication of the Talentlytica team in creating assessment solutions that are not only sophisticated, but also relevant to the needs of the modern world of work.\nTalentlytica participates in ICAL 2024, Indonesia’s psychometric technology becomes global.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Science and Technology",
      "Economy, Business and Finance"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": {
      "syndicated": false,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-10-18T00:18:00.068+03:00",
    "updated": "2024-10-18T00:18:00.068+03:00"
  },
  {
    "uuid": "e1c4142c75426856f24d5841da49339fbd494a71",
    "url": "https://www.cope.es/actualidad/espana/noticias/oproximo--guterres-celebra-anuncio-entregar-medicamentos-muy-necesarios-poblacion-gaza-los-rehenes-20240119_3100219",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Europa Press",
    "published": "2024-01-19T06:33:00Z",
    "title": "O.Próximo.- Guterres celebra el anuncio de entregar medicamentos \"muy necesarios\" a la población de Gaza y los rehenes - España - COPE",
    "text": "O.Próximo.- Guterres celebra el anuncio de entregar medicamentos \"muy necesarios\" a la población de Gaza y los rehenes Europa Press Tiempo de lectura: 2' Actualizado 07:34 La llegada de estos suministros \"es alentadora, aunque es necesario que llegue mucha más ayuda\", afirma el jefe de la ONU El secretario general de la ONU, António Guterres, ha celebrado el anuncio de la entrada de medicinas y ayuda humanitaria a la Franja de Gaza gracias a un acuerdo alcanzado en los últimos días entre Israel y el Movimiento de Resistencia Islámica (Hamás), según confirmaron las autoridades de Qatar, que actúan como mediadoras entre las partes. \"(Guterres) acoge con agrado el anuncio de una operación para entregar medicamentos y suministros médicos adicionales y muy necesarios a la población civil de la Franja de Gaza y para los rehenes actualmente retenidos\", ha indicado el portavoz del secretario general, Stéphane Dujarric, durante una rueda de prensa, en la que ha agradecido el papel de Qatar y Francia \"por sus esfuerzos\". En este sentido, ha manifestado que \"la entrada de estos suministros y ayuda humanitaria es alentadora, aunque es necesario que llegue mucha más ayuda\" al enclave, mientras que ha instado a \"todos los actores relevantes\" a garantizar que llegue \"suficiente ayuda\" allá \"donde sea necesaria\" y ha pedido la \"reactivación del sector privado para llevar productos básicos a la Franja\". Al mismo tiempo, Guterres ha reiterado su llamamiento a un \"alto el fuego humanitario inmediato\" y una \"liberación inmediata e incondicional de los rehenes\", y por otro lado ha expresado su \"continúa preocupación por el aumento de la escalada en la región\", pidiendo una reducción urgente de las tensiones. \"Necesitamos ver el fin de la violencia. Existen diferentes marcos y creo que quizás, especialmente, necesitamos obtener compromisos de las partes más interesadas para avanzar hacia ese objetivo, y luego podremos ver cuál es el mejor marco para llegar allí\", ha declarado su portavoz al ser preguntado sobre el papel del secretario de cara a las negociaciones de la comunidad internacional. El Movimiento de Resistencia Islámica (Hamás) lanzó a comienzos de octubre una serie de ataques que dejaron unos 1.200 muertos y cerca de 240 secuestrados. El Ejército de Israel respondió con una cruenta contraofensiva contra la Franja de Gaza que se cobra ya más de 24.600 vidas palestinas. A eso se suman más de 360 muertos en operaciones de las fuerzas de seguridad y ataques por parte de colonos en Cisjordania y Jerusalén Este. - item no encontrado",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "positive",
    "categories": [
      "War, Conflict and Unrest",
      "Health"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-01-19T08:41:18.246+02:00",
    "updated": "2024-01-19T08:41:18.246+02:00"
  },
  {
    "uuid": "308a7fd010e3bd127fdc55cb38248d29d0e79b1c",
    "url": "https://www.sdpnoticias.com:443/espectaculos/famosos/mariana-seoane-le-tira-a-susana-zabaleta-por-ser-novia-de-ricardo-perez-yo-no-mantengo-a-nadie",
    "ord_in_thread": 0,
    "author": "Sonia Meneses",
    "published": "2025-04-30T22:05:00Z",
    "title": "Mariana Seoane le tira a Susana Zabaleta por ser novia de Ricardo Pérez: \"Yo no mantengo a nadie\"",
    "text": "Mariana Seoane -de 48 años de edad- le tiró a Susana Zabaleta por ser novia de Ricardo Pérez durante la alfombra roja de los premios ‘Las Diosas de Plata 2025′.\nY es que Mariana Seoane dijo que, a diferencia de Susana Zabaleta -de 60 años de edad-, “Yo no mantengo a nadie”.\nAsí le tiró Mariana Seoanea Susana Zabaleta por ser novia de Ricardo Pérez\nDurante un encuentro con la prensa el 29 de abril en la alfombra roja de los premios ‘Las Diosas de Plata 2025′, Mariana Seoane le tiró a Susana Zabaleta por ser novia de Ricardo Pérez -de 30 años de edad-.\n“Yo no soy Susana Zabaleta, yo no mantengo a nadie”\nMariana Seoane\nEste comentario surgió luego de que Mariana Seoane presentará su próximo lanzamiento musical ‘Amantes del Peligro’.\nY es que la canción, en colaboración con un cantante peruano, hablaría sobre las relaciones entre mujeres mayores y hombres menores\nEsta clase de noviazgos poco comunes no molestarían a Mariana Seoane cuestionando “¿por qué a nosotras no nos pueden gustar los hombres más jóvenes?”; sin embargo, dejó en claro que no es su estilo.\nPues, como se mencionó anteriormente, la cantante destacó que ella no tiene los mismos gustos que Susana Zabaleta para elegir a sus parejas.\nA lo que cabe mencionar, Mariana Seoane ha tenido diversas parejas sentimentales, nunca se ha casado, no tiene hijos y actualmente estaría soltera.\nPor su parte, Susana Zabaleta no ha respondido de ninguna forma las criticas en contra de su relación con Ricardo Pérez\nAsí ha sido la relación de Susana Zabaleta y Ricardo Pérez\nSusana Zabaleta y Ricardo Pérez se habrían conocido durante las grabaciones de la segunda temporada del programa ‘Divina Comida’ de HBO.\nY aunque Susana Zabaleta y Ricardo Pérez comenzaron a salir en noviembre de 2023, la pareja no confirmó su relación sino hasta febrero de 2024.\nEn cuanto a su primer aniversario, Susana Zabaleta y Ricardo Pérez lo celebraron el pasado domingo 27 de abril, y compartieron las fotos a través de sus cuentas oficiales en Instagram.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "negative",
    "categories": [
      "Human Interest",
      "Lifestyle and Leisure"
    ],
    "topics": [
      "Human Interest->celebrity",
      "Lifestyle and Leisure->lifestyle"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": true,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
      "persons": [
        {
          "name": "Ricardo Pérez",
          "sentiment": "negative"
        },
        {
          "name": "Mariana Seoanea Susana Zabaleta",
          "sentiment": "neutral"
        },
        {
          "name": "Mariana Seoane\nEste",
          "sentiment": "neutral"
        }
      ],
      "locations": [],
      "organizations": []
    },
    "syndication": {
      "syndicated": null,
      "syndicate_id": null,
      "first_syndicated": false
    },
    "trust": {
      "categories": [],
      "bias": null,
      "source": {
        "type": null,
        "city": null,
        "state": null,
        "country": null,
        "domain_type": null,
        "agency": null,
        "organization_name": null
      }
    },
    "rating": null,
    "crawled": "2025-05-01T01:23:05.185+03:00",
    "updated": "2025-04-30T22:30:20.000+00:00"
  },
  {
    "uuid": "b6d3c7ebe17b185a026bf932be4da0fda04782aa",
    "url": "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-exceeds-market-returns:-some-facts-to-consider-0",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Zacks",
    "published": "2024-01-05T23:00:00Z",
    "title": "Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider",
    "text": "In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $70.83, marking a +0.67% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.18%. Meanwhile, the Dow experienced a rise of 0.07%, and the technology-dominated Nasdaq saw an increase of 0.1%.\nThe drugmaker's shares have seen an increase of 14.59% over the last month, surpassing the Medical sector's gain of 6.12% and the S&P 500's gain of 2.75%.\nThe upcoming earnings release of Ligand Pharmaceuticals will be of great interest to investors. The company's earnings per share (EPS) are projected to be $0.58, reflecting a 57.35% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $24.54 million, showing a 51.29% drop compared to the year-ago quarter.\nAny recent changes to analyst estimates for Ligand Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.\nOur research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.\nThe Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.16% lower. Ligand Pharmaceuticals presently features a Zacks Rank of #4 (Sell).\nIn terms of valuation, Ligand Pharmaceuticals is presently being traded at a Forward P/E ratio of 15.92. This represents a discount compared to its industry's average Forward P/E of 22.55.\nThe Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries.\nThe Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.\nDon't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.\nOnly $1 to See All Zacks' Buys and Sells\nWe're not kidding.\nSeveral years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.\nThousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.\nSee Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report To read this article on Zacks.com click here.\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Health",
      "Science and Technology",
      "Economy, Business and Finance"
    ],
    "external_links": [
      "https://www.zacks.com/stock/news/2206595/ligand-pharmaceuticals-lgnd-exceeds-market-returns-some-facts-to-consider?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=LGND&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_NASDAQ_ZU_ZU_TALEOFTAPE_554_01052024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328",
      "https://zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=LGND&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_554&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://zacks.com/stock/news/2206595/ligand-pharmaceuticals-lgnd-exceeds-market-returns-some-facts-to-consider?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_NASDAQ_ZU_ZU_TALEOFTAPE_554_01052024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_6v2-2206595",
      "https://www.zacks.com/registration/pfp",
      "https://www.zacks.com/registration/pfp/",
      "https://www.zacks.com/stock/news/2206595/ligand-pharmaceuticals-lgnd-exceeds-market-returns-some-facts-to-consider"
    ],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [
        {
          "name": "ligand pharmaceuticals",
          "sentiment": "negative"
        },
        {
          "name": "s&p",
          "sentiment": "none"
        }
      ],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-01-06T02:34:12.046+02:00",
    "updated": "2024-01-06T02:34:12.046+02:00"
  }
]